The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man.
Open accessAbstract
BACKGROUND: Measurement of chromogranin A (CgA) levels in blood can be used to monitor neuroendocrine tumors (NETs). CgA levels may also be elevated in several other endocrine and non-endocrine diseases. It is well known that drugs affecting acid gastric secretion can increase gastrin. Proton-pump inhibitors are extensively used but only a few data have been reported on their effects on CgA secretion. DESIGN: The aim of the study was to evaluate the short-term effect of low dosages of omeprazole (OM) on CgA levels and to sensitize endocrinologists to possible false positive values of CgA in order to prevent expensive diagnostic work-up in searching for NETs. SUBJECTS AND METHODS: Thirty-five female and nine male in-patients (18-81 years) were studied. Mild or severe hypertension in 20 patients needed therapy. Endocrine and metabolic diseases were diagnosed in the majority of patients. CgA levels were evaluated before and during OM therapy (10 mg/day, orally). RESULTS: Without OM therapy, CgA levels were 64+/-6 microg/l. Elevated baseline CgA levels were found in nine subjects. CgA levels were significantly related to age (P<0.001), creatinine levels (P=0.03) and the severity of hypertension (P=0.002). On short-term OM therapy (n=42; 18.8+/-2.4 days; range 5-90 days) a significant (P<0.001) increase in CgA (145+/-22 microg/l) from baseline (63+/-7 microg/l) levels was found. The average net CgA increase on short-term OM therapy was 93+/-20 microg/l. There was a significant correlation between baseline CgA levels and CgA increase on short-term OM therapy (P=0.004) but not between the increase in CgA and the duration of the therapy. CONCLUSIONS: An increase in CgA levels quickly follows the start of low dosages of OM. This release is more pronounced when the baseline CgA levels are already increased by slight renal insufficiency or severe hypertension. In this common clinical situation an intensive work-up for NETs is not justified before reassessment of CgA after the withdrawal of OM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Giusti et al (2004) observed in six of seven patients a significant decrease of CgA levels after discontinuation of omeprazole.”
From Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours (2011) · cites this paper as Giusti et al, 2004
In the citing paper
“Even a five-fold higher exposure to PPIs has been observed in poor metabolisers (PMs) than in extensive metabolisers of CYP2C19 (Desta et al, 2002; Giusti et al, 2004).”
From Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours (2011) · cites this paper as Giusti et al, 2004
In the citing paper
“As the prevalence of PMs in Caucasian people is 1–3%, in some cases, the CgA could still be false positive after 2 weeks of discontinuation.”
From Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours (2011) · cites this paper as Giusti et al, 2004
In the citing paper
“However, the effect of short-term PPI therapy on CgA levels has not been studied systematically, and there is very little information on the duration of the effect of PPI on CgA levels, and thus on how long PPI need to be stopped before their effect on CgA has disappeared.”
From Effect of Short-Term Proton Pump Inhibitor Treatment and Its Discontinuation on Chromogranin A in Healthy Subjects (2012) · cites this paper as [9]
Citations
Cites
Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism
Desta, Z., Zhao, X., Shin, J.-G., & Flockhart, D. A. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241120-00002 · Cited by 942
The Chromogranin–Secretogranin Family
Taupenot, L., Harper, K. L., & O'Connor, D. T. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021405 · Cited by 819
Secretion of Chromogranin A by Peptide-Producing Endocrine Neoplasms
O'Connor, D. T., & Deftos, L. J. (1986) · New England Journal of Medicine · doi:10.1056/nejm198605013141803 · Cited by 477
The Release of Protein from the Stimulated Adrenal Medulla
Banks, P., & Helle, K. (1965) · Biochemical Journal · doi:10.1042/bj0970040c · Cited by 274
Marked increase in gastric acid secretory capacity after omeprazole treatment.
Waldum, H. L., Arnestad, J. S., Brenna, E., Eide, I., Syversen, U., & Sandvik, A. K. (1996) · Gut · doi:10.1136/gut.39.5.649 · Cited by 243
Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity.
Sharma, B. K., Walt, R. P., Pounder, R. E., Gomes, M. D., Wood, E. C., & Logan, L. H. (1984) · Gut · doi:10.1136/gut.25.9.957 · Cited by 240
O'Connor, D. T., Pandlan, M. R., Carlton, E., Cervenka, J. H., & Hslao, R. J. (1989) · Clinical Chemistry · doi:10.1093/clinchem/35.8.1631 · Cited by 168
Proton pump inhibitors: an update.
Vanderhoff, B., & Tahboub, R. (2002) · PubMed · Cited by 145
Chromogranin A Storage and Secretion
Hsiao, R. J., Parmer, R. J., TAKIYYUDDIN, M. A., & O’Connor, D. T. (1991) · Medicine · doi:10.1097/00005792-199101000-00003 · Cited by 125
Chromogranins, widespread in endocrine and nervous tissue, bind Ca2+
Reiffen, F. U., & Gratzl, M. (1986) · FEBS Letters · doi:10.1016/0014-5793(86)80187-9 · Cited by 121
Cited by
ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum
Niederle, B., Pape, U.-F., Costa, F., Gross, D., Kelestimur, F., Knigge, U., Öberg, K., Pavel, M., Perren, A., Toumpanakis, C., et al. (2016) · Neuroendocrinology · doi:10.1159/000443170 · Cited by 474
Pape, U.-F., Perren, A., Niederle, B., Gross, D., Gress, T., Costa, F., Arnold, R., Denecke, T., Plöckinger, U., Salazar, R., et al. (2012) · Neuroendocrinology · doi:10.1159/000335629 · Cited by 465
Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease
Modlin, I. M., Gustafsson, B. I., Moss, S. F., Pavel, M., Tsolakis, A. V., & Kidd, M. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1006-3 · Cited by 387
Chromogranin A: is it a useful marker of neuroendocrine tumors?
Campana, D., Nori, F., Piscitelli, L., Morselli-Labate, A. M., Pezzilli, R., Corinaldesi, R., & Tomassetti, P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.1535 · Cited by 248
Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management
Ma, Z.-Y., Gong, Y.-F., Zhuang, H.-K., Zhou, Z.-X., Huang, S.-Z., Zou, Y.-P., Huang, B.-W., Sun, Z.-H., Zhang, C.-Z., Tang, Y.-Q., et al. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i19.2305 · Cited by 196
Metadata
- Authors
- Giusti, M., Sidoti, M., Augeri, C., Rabitti, C., & Minuto, F.
- Affiliations
- University of Genoa (IT)
- Corresponding author
- Giusti, M
- ORCID
- Giusti, M
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-03-01
- Volume
- 150
- Issue
- 3
- Pages
- 299-303
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2105319126
- Semantic Scholar
- ffbd2a34921c1ef1f2a65a2f2f9cffcd0c3cb196
- Cited by
- 111
- References
- 24
- Citations by year
- 2026: 1 · 2024: 3 · 2023: 3 · 2022: 3 · 2021: 5 · 2020: 6 · 2019: 7 · 2018: 6 · 2017: 3 · 2016: 6 · 2015: 5 · 2014: 5 · 2013: 3 · 2012: 11
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- chromogranin A, proton pump inhibitors, neuroendocrine tumors, gastrin, gastric acid secretion, hypertension, renal failure, antihypertensive therapy
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Chromogranins, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Omeprazole, Biomarkers, Tumor, Neuroendocrine Tumors, Chromogranin A, Proton Pump Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. https://app.cochat.ai/papers/10.1530/eje.0.1500299
- The paper
- Giusti, M., Sidoti, M., Augeri, C., Rabitti, C., & Minuto, F. (2004). Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. European Journal of Endocrinology. https://doi.org/10.1530/eje.0.1500299
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.